|Bid||232.59 x 900|
|Ask||234.16 x 900|
|Day's Range||231.86 - 236.21|
|52 Week Range||128.52 - 237.47|
|Beta (5Y Monthly)||1.46|
|PE Ratio (TTM)||111.61|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
IQVIA (IQV) could produce exceptional returns because of its solid growth attributes.
Total global spending on COVID-19 vaccines is projected to reach $157 billion by 2025, driven by mass vaccination programs underway and "booster shots" expected every two years, according to a report by U.S. health data company IQVIA Holdings Inc released on Thursday. Booster shots are likely to follow initial vaccinations every two years, the report said, based on current data on the duration of effect of the vaccines. The United States is preparing for the possibility that a booster shot will be needed between nine to 12 months after people receive their first full inoculations against COVID-19, a White House official said earlier this month.
IQVIA (IQV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.